Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies

Antibody-directed cancer chemotherapy in the form of antibody-drug conjugates (ADCs) may improve the therapeutic index with the potential to enhance efficacy and decrease systemic toxicity. ADCs consist of three key components including an antibody that specifically binds to the target, a toxic agen...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacology & therapeutics (Oxford) 2017-02, Vol.170, p.8-13
Main Authors: Almhanna, Khaldoun, Prithviraj, Gopi K, Veiby, Petter, Kalebic, Thea
Format: Article
Language:English
Subjects:
Animals
Antibodies - administration & dosage
Antineoplastic Agents - administration & dosage
Apoptosis - drug effects
Drug Delivery Systems
Drug Design
Gastrointestinal Neoplasms - drug therapy
Gastrointestinal Neoplasms - immunology
Gastrointestinal Neoplasms - pathology
Guanylate Cyclase - immunology
Humans
Immunoconjugates - administration & dosage
Molecular Targeted Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antibody-directed cancer chemotherapy in the form of antibody-drug conjugates (ADCs) may improve the therapeutic index with the potential to enhance efficacy and decrease systemic toxicity. ADCs consist of three key components including an antibody that specifically binds to the target, a toxic agent and a linker which releases the toxic agent inside tumor cells. A novel ADC, MLN0264 (TAK-264) was recently investigated in patients with gastrointestinal (GI) malignancies. TAK-264 is an anti- guanylyl cyclase C (GCC) antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE) (linker and toxin licensed from Seattle Genetics). Following binding to GCC, the ADC is internalized and transported to lysosomes where MMAE is released to bind to tubulin, leading to cell cycle arrest and apoptosis. This GCC targeting ADC has been evaluated in clinical studies in patients with advanced gastrointestinal malignancies. The early findings from Phase 1 study have shown preliminary activity signals in gastric, gastroesophageal, and pancreatic cancer. Results from two phase II studies in pancreatic and gastoesophageal adenocarcinoma showed only limited activity. Antibody-drug-conjugates offer a promising therapeutic modality aimed at providing target-directed cancer chemotherapy. Herein we discuss the GCC target and gastrointestinal malignancies where GCC based targeted therapies could further evolve and offer a significant clinical benefit.
ISSN:0163-7258
1879-016X
DOI:10.1016/j.pharmthera.2016.10.007